Evidence map›Paper›PMID 32364035›Full record

ArticleThe Journal of international medical research2020

Effect of sitagliptin on expression of skeletal muscle peroxisome proliferator-activated receptor

Yuntao Liu, Feng Xu, Pan Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Beneficial effects of MgSOMolecular biology reports · 2022
    Article
  9. Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yuntao LiuDepartment of Endocrinology, Affiliated Renhe Hospital of China Three Gorges University, The Second Clinical Medical College of China Three Gorges University, Yichang, China.ORCID https://orcid.org/0000-0002-6411-5865
Feng XuYichang Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, China Three Gorges University, Yichang, China.
Pan JiangDepartment of Endocrinology, Affiliated Renhe Hospital of China Three Gorges University, The Second Clinical Medical College of China Three Gorges University, Yichang, China.
China Three Gorges University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of sitagliptin on skeletal muscle expression of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), irisin, and phosphoadenylated adenylate activated protein kinase (p-AMPK) in a rat model of type 2 diabetes mellitus (T2DM).

methodsA high-fat diet/streptozotocin T2DM rat model was established. Rats were divided into T2DM, low-dose sitagliptin (ST1), high-dose sitagliptin (ST2), and normal control groups (NC). PGC-1α, irisin, and p-AMPK protein levels in skeletal muscle were measured by western blot, and PCG-1α and Fndc5 mRNA levels were assessed by reverse transcription-polymerase chain reaction.

resultsFasting plasma glucose (FPG), fasting insulin (FIns), homeostatic model assessment-insulin resistance (HOMA-IR), and tumor necrosis factor-α (TNF-α) were significantly up-regulated in the T2DM compared with the other groups, and FPG, FIns, total cholesterol, triglycerides, TNF-α, and HOMA-IR were significantly down-regulated in the ST2 compared with the ST1 group. PGC-1α, irisin, and p-AMPK expression levels decreased successively in the ST2, ST1, and DM groups compared with the NC, and were all significantly up-regulated in the ST2 compared with the ST1 group.

conclusionDown-regulation of PGC-1α and irisin in skeletal muscle may be involved in T2DM. Sitagliptin can dose-dependently up-regulate PCG-1α and irisin, potentially improving insulin resistance and glycolipid metabolism and inhibiting inflammation.

Indexed as

AMP-Activated Protein Kinase KinasesAnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diet, High-FatDose-Response Relationship, DrugDown-RegulationFibronectinsGlycolipidsHumansHypoglycemic AgentsMaleMuscle, SkeletalPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaProtein KinasesRatsAMP-Activated Protein Kinase KinasesFibronectinsFNDC5 protein, ratGlycolipidsHypoglycemic AgentsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPpargc1a protein, ratProtein KinasesSitagliptin PhosphateStreptozocindiabetes mellitus type 2glycoplipid metabolisminsulin resistanceirisinPeroxisome proliferator-activated receptor γ coactivator-1αphosphoadenylated adenylate activated protein kinasesitagliptin

Identifiers

PMID32364035
PMCPMC7218978
OpenAlexW3021352072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.